Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cdp1
- Development stage
- Phase 1
- Lead developer
- Dragonboat Biopharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CDP1 is a recombinant chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is developed as a biosimilar to cetuximab (original brand name Erbitux), designed to bind EGFR and inhibit its signaling, thereby blocking tumor cell proliferation and survival. CDP1 has been evaluated in clinical trials for advanced solid tumors, with studies comparing its pharmacokinetics, safety, and immunogenicity to Erbitux in healthy volunteers and patients with cancer[6][8]. The drug is being developed by Dragonboat Biopharmaceutical Company Limited.
- Other names
- Recombinant anti-EGFR human mouse chimeric monoclonal antibody
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on cdp1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cdp1.